MCID: CLR109
MIFTS: 50

Colorectal Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Colorectal Adenocarcinoma

MalaCards integrated aliases for Colorectal Adenocarcinoma:

Name: Colorectal Adenocarcinoma 12 15 17
Adenocarcinoma of Large Intestine 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0050861
UMLS 71 C1319315

Summaries for Colorectal Adenocarcinoma

Disease Ontology : 12 A colorectal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Colorectal Adenocarcinoma, also known as adenocarcinoma of large intestine, is related to colorectal adenoma and adenocarcinoma. An important gene associated with Colorectal Adenocarcinoma is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are ERK Signaling and Developmental Biology. The drugs Iron and Hepcidins have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and lung, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Colorectal Adenocarcinoma

Diseases related to Colorectal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 548)
# Related Disease Score Top Affiliating Genes
1 colorectal adenoma 32.8 VEGFA TP53 MSH2 MLH1 KRAS HRAS
2 adenocarcinoma 31.5 VEGFA TP53 MSH2 MLH1 KRT7 KRT20
3 adenoma 31.3 TP53 MSH2 MLH1 KRT7 KRAS CTNNB1
4 appendix adenocarcinoma 31.3 KRT7 KRT20 KRAS HRAS CEACAM5 CDX2
5 bladder adenocarcinoma 31.2 KRT7 KRT20 CDX2
6 rectum cancer 31.2 MSH2 MLH1 KRT20 KRAS HRAS CEACAM5
7 colon adenocarcinoma 31.1 VEGFA TP53 MLH1 KRT20 KRAS EGFR
8 gastrointestinal stromal tumor 31.0 VEGFA TP53 KRAS EGFR CDH1 BRAF
9 mucinous adenocarcinoma 31.0 VEGFA TP53 MLH1 KRT7 KRT20 KRAS
10 familial adenomatous polyposis 31.0 TP53 MSH2 MLH1 KRAS HRAS CTNNB1
11 lynch syndrome 30.9 TP53 MSH2 MLH1 KRAS HRAS EGFR
12 exanthem 30.8 VEGFA KRAS HRAS EGFR
13 villous adenoma 30.8 MLH1 KRT20 KRAS HRAS CEACAM5 CDX2
14 urachal adenocarcinoma 30.8 KRAS CEACAM5 BRAF
15 small intestine adenocarcinoma 30.7 MSH2 MLH1 KRAS HRAS
16 lymphoepithelioma-like carcinoma 30.7 KRT7 KRT20 CDH1
17 rectum adenocarcinoma 30.7 TP53 MSH2 MLH1 KRT7 KRT20 KRAS
18 goblet cell carcinoid 30.7 KRT20 CTNNB1 CDH1
19 in situ pulmonary adenocarcinoma 30.6 KRAS HRAS EGFR
20 mucinous bronchioloalveolar adenocarcinoma 30.6 KRT7 KRT20 CEACAM5 CDX2
21 cystitis cystica 30.6 KRT7 KRT20 CTNNB1 CDX2
22 intestinal obstruction 30.6 KRT7 KRT20 CEACAM5 CDX2
23 sebaceous adenocarcinoma 30.5 TP53 MSH2 MLH1
24 neuroendocrine carcinoma 30.5 KRT7 KRT20 CEACAM5 CDH1
25 muir-torre syndrome 30.5 TP53 MSH2 MLH1
26 in situ carcinoma 30.5 TP53 HRAS EGFR CDH1
27 pleomorphic adenoma 30.5 TP53 KRT7 HRAS CTNNB1
28 neuroendocrine tumor 30.4 VEGFA KRT20 HRAS CDX2
29 thyroid carcinoma 30.4 TP53 HRAS CTNNB1 CDH1 BRAF
30 esophagitis 30.4 VEGFA TP53 EGFR
31 colitis 30.4 MSH2 MLH1 CTNNB1 BRAF
32 renal cell carcinoma, nonpapillary 30.4 VEGFA TP53 KRT7 KRT20 HRAS EGFR
33 familial colorectal cancer 30.4 TP53 MSH2 MLH1 CDH1 BRAF
34 mesothelioma, malignant 30.4 KRT7 KRT20 CTNNB1 CEACAM5 CDH1
35 cystitis 30.4 VEGFA TP53 KRT7 KRT20 CDX2 CDH1
36 intrahepatic cholangiocarcinoma 30.4 TP53 KRT7 KRT20 KRAS EGFR CTNNB1
37 rhabdomyosarcoma 30.4 VEGFA TP53 MSH2 KRAS HRAS EGFR
38 cystadenocarcinoma 30.4 VEGFA TP53 KRT7 HRAS CEACAM5 BRAF
39 chordoma 30.3 VEGFA TP53 KRT7 EGFR CTNNB1 CDH1
40 breast ductal carcinoma 30.3 VEGFA TP53 KRT7 EGFR CTNNB1 CDH1
41 cowden syndrome 30.3 TP53 MSH2 MLH1 HRAS EGFR
42 bronchiolo-alveolar adenocarcinoma 30.3 KRT7 KRT20 KRAS EGFR CEACAM5 CDX2
43 retinitis pigmentosa 11 30.3 TP53 HRAS EGFR
44 squamous cell carcinoma 30.2 VEGFA TP53 HRAS EGFR CTNNB1 CEACAM5
45 tubular adenocarcinoma 30.2 KRT7 KRT20 EGFR CTNNB1 CEACAM5 CDX2
46 carcinosarcoma 30.2 TP53 KRT7 KRAS HRAS EGFR CTNNB1
47 lymphoma 30.2 TP53 PIM2 MSH2 EGFR CDH1 BRAF
48 lung cancer susceptibility 3 30.2 VEGFA TP53 KRT7 KRT20 KRAS HRAS
49 cholangiocarcinoma 30.2 TP53 KRT7 KRT20 KRAS EGFR CTNNB1
50 signet ring cell adenocarcinoma 30.1 TP53 MSH2 MLH1 KRT7 KRT20 KRAS

Graphical network of the top 20 diseases related to Colorectal Adenocarcinoma:



Diseases related to Colorectal Adenocarcinoma

Symptoms & Phenotypes for Colorectal Adenocarcinoma

GenomeRNAi Phenotypes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.92 AURKA EGFR HRAS KRAS PIM2 BRAF
2 Decreased viability GR00106-A-0 10.92 KRAS
3 Decreased viability GR00173-A 10.92 CDK8
4 Decreased viability GR00221-A-1 10.92 AURKA CDH1 CDK8 EGFR HRAS KRAS
5 Decreased viability GR00221-A-2 10.92 AURKA CDK8 HRAS KRAS
6 Decreased viability GR00221-A-3 10.92 HRAS
7 Decreased viability GR00221-A-4 10.92 AURKA CDK8 EGFR BRAF
8 Decreased viability GR00231-A 10.92 AURKA
9 Decreased viability GR00301-A 10.92 CDH1 CDK8 KRAS PIM2 BRAF MSH2
10 Decreased viability GR00381-A-1 10.92 KRAS BRAF
11 Decreased viability GR00402-S-2 10.92 AURKA CDH1 CDK8 EGFR HRAS KRAS
12 Decreased cell migration GR00055-A-1 9.97 AURKA BRAF CDK8 CTNNB1 EGFR HRAS
13 Decreased viability in esophageal squamous lineage GR00235-A 9.9 AURKA BRAF CDH1 CDK8 CTNNB1 FABP6
14 Decreased cella89culturea89derived Hepatitis C virus (HCVcc; Luca89Jc1) infection GR00234-A-2 9.5 BRAF CDK8 EGFR
15 Increased cell migration GR00055-A-3 9.43 AURKA BRAF CTNNB1 EGFR HRAS KRAS
16 Increased cell viability after pRB stimulation GR00230-A-1 8.92 AURKA CDK8 EGFR PIM2

MGI Mouse Phenotypes related to Colorectal Adenocarcinoma:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.33 AURKA BRAF CDH1 CDX2 CTNNB1 EGFR
2 homeostasis/metabolism MP:0005376 10.27 BRAF CDH1 CDX2 CTNNB1 EGFR FABP6
3 cardiovascular system MP:0005385 10.26 BRAF CDH1 CDK8 CDX2 CTNNB1 EGFR
4 digestive/alimentary MP:0005381 10.26 BRAF CDH1 CDX2 CTNNB1 EGFR HRAS
5 growth/size/body region MP:0005378 10.26 AURKA BRAF CDH1 CDK8 CDX2 CTNNB1
6 embryo MP:0005380 10.21 AURKA BRAF CDH1 CDK8 CDX2 CTNNB1
7 mortality/aging MP:0010768 10.21 AURKA BRAF CDH1 CDK8 CDX2 CTNNB1
8 endocrine/exocrine gland MP:0005379 10.19 BRAF CDH1 CDX2 CTNNB1 EGFR HRAS
9 integument MP:0010771 10.13 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
10 neoplasm MP:0002006 10.1 AURKA BRAF CDH1 CDX2 CTNNB1 EGFR
11 craniofacial MP:0005382 10.08 BRAF CTNNB1 EGFR HRAS KRAS TP53
12 limbs/digits/tail MP:0005371 9.95 BRAF CDX2 CTNNB1 EGFR KRAS TP53
13 no phenotypic analysis MP:0003012 9.86 AURKA CDH1 CTNNB1 EGFR HRAS KRAS
14 normal MP:0002873 9.81 BRAF CDH1 CDX2 CTNNB1 EGFR HRAS
15 renal/urinary system MP:0005367 9.56 BRAF CTNNB1 EGFR HRAS KRAS KRT7
16 respiratory system MP:0005388 9.23 BRAF CTNNB1 EGFR HRAS KRAS MLH1

Drugs & Therapeutics for Colorectal Adenocarcinoma

Drugs for Colorectal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 139)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
2 Hepcidins Phase 4
3 Ferric Compounds Phase 4
4 Iron Supplement Phase 4
5
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
6
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
7
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
8
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599 43805
9
Fluorouracil Approved Phase 3 51-21-8 3385
10
leucovorin Approved Phase 3 58-05-9 6006 143
11
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
12
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
13
Irinotecan Approved, Investigational Phase 2, Phase 3 97682-44-5, 100286-90-6 60838
14
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
15
Panitumumab Approved, Investigational Phase 3 339177-26-3 50070211
16
Nicotine Approved Phase 3 54-11-5 942 89594
17
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
18
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
19
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
20
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
21
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 6221 5280795
22
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
23 Antibiotics, Antitubercular Phase 3
24 Anti-Bacterial Agents Phase 3
25 Pharmaceutical Solutions Phase 3
26
Liposomal doxorubicin Phase 3 31703
27 Immunologic Factors Phase 2, Phase 3
28 Immunosuppressive Agents Phase 2, Phase 3
29 Antimetabolites Phase 3
30 Antineoplastic Agents, Immunological Phase 2, Phase 3
31 Angiogenesis Inhibitors Phase 2, Phase 3
32 topoisomerase I inhibitors Phase 2, Phase 3
33 Topoisomerase Inhibitors Phase 2, Phase 3
34 Trace Elements Phase 3
35 Micronutrients Phase 3
36 Vitamins Phase 3
37 Nutrients Phase 3
38 Vitamin B Complex Phase 3
39 Vitamin B9 Phase 3
40 Protective Agents Phase 3
41 Folate Phase 3
42 Antidotes Phase 3
43 Hormones Phase 3
44 Hematinics Phase 3
45 Calcium, Dietary Phase 3
46 Ergocalciferols Phase 3
47 Calciferol Phase 3
48 Vitamin D2 Phase 3
49 Mitomycins Phase 2, Phase 3
50 Formyltetrahydrofolates Phase 3

Interventional clinical trials:

(show top 50) (show all 147)
# Name Status NCT ID Phase Drugs
1 Study of Cetuximab in Combination With Chemotherapy for the First Treatment of Metastatic Colorectal Cancer Unknown status NCT01564810 Phase 4 Cetuximab;chemotherapy of mFOLFOX6 or FOLFIRI
2 An Open Label Study of Intravenous Iron (FERINJECT) in Colorectal Adenocarcinoma Related Anaemia to Identify Potential Biomarkers of Responsiveness to Intravenous Iron Completed NCT02057471 Phase 4 Intravenous ferric carboxymaltose
3 An Open Label Study to Determine the Efficacy of Ferric Carboxymaltose in Preoperative Colorectal Cancer Related Anaemia, and to Develop Biomarkers to Predict Response to This Treatment Strategy Completed NCT01701310 Phase 4 Ferric carboxymaltose;Ferrous Sulphate
4 Study of Avastin in Combination With Chemotherapy for the First Line Treatment of RAS Mutant Unresectable Colorectal Liver-limited Metastases Completed NCT01972490 Phase 4 avastin;mFOLFOX6
5 A Multicenter,Randomized, Double-blind, Placebo-controlled Trial of Famitinib in Patients With Advanced Colorectal Adenocarcinoma Unknown status NCT02390947 Phase 3 Famitinib;Placebo
6 Drug Treatment for Bowel Cancer: Making the Best Choices When a Milder Treatment is Needed Unknown status NCT00070213 Phase 3 FOLFOX regimen;capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
7 A Three-Arm Randomised Controlled Trial Comparing Either Continuous Chemotherapy Plus Cetuximab or Intermittent Chemotherapy With Standard Continuous Palliative Combination Chemotherapy With Oxaliplatin and a Fluoropyrimidine in First Line Treatment of Metastatic Colorectal Cancer (COIN) Unknown status NCT00182715 Phase 3 capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
8 A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma Completed NCT02788279 Phase 3 Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody;Cobimetinib;Regorafenib
9 A Randomized, Multicenter Phase III Trial to Assess the Efficacy and Safety of Bevacizumab and Capecitabine as Maintenance Treatment, After Initial Combination Treatment With Capecitabine, Oxaliplatin and Bevacizumab in Patients With Metastatic Colorectal Adenocarcinoma Completed NCT00623805 Phase 3 Bevacizumab;Capecitabine;Oxaliplatin
10 The Impact of Positron Emission Tomography (PET) Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases: A Prospective, Multicentre Randomized Clinical Trial Completed NCT00265356 Phase 3
11 Phase III Trial of Bevacizumab (NSC 704865), Oxaliplatin (NSC 266046), Fluorouracil and Leucovorin Versus Oxaliplatin, Fluorouracil and Leucovorin Versus Bevacizumab Alone in Previously Treated Patients With Advanced Colorectal Cancer Completed NCT00025337 Phase 3 oxaliplatin;leucovorin calcium;fluorouracil
12 A Randomized Phase I/III Study Of Systematic Chemotherapy With Or Without Hepatic Chemoembolization For Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum Completed NCT00023868 Phase 3 FOLFIRI regimen;cisplatin;doxorubicin hydrochloride;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C
13 A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum Completed NCT00003594 Phase 3 irinotecan;fluorouracil;leucovorin calcium;oxaliplatin
14 Randomized Trial of Treatment Strategy for Chemotherapy in Colorectal Cancer, FFCD 2000-05 Completed NCT00126256 Phase 3 5-fluorouracil;leucovorin;irinotecan;oxaliplatin
15 A Prospective, Randomized, One-center Study Comparing Hepatic Arterial Infusion Plus Chemotherapy ± Target Therapy and Chemotherapy ± Target Therapy Alone in Patients With Unresectable Colorectal Cancer Liver Metastases Recruiting NCT03125161 Phase 3 HAI;chemotherapy ± target therapy
16 Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS) Recruiting NCT04094688 Phase 3 Bevacizumab;Oxaliplatin;Leucovorin Calcium;Fluorouracil;Irinotecan Hydrochloride;Irinotecan
17 Randomized Phase III Trial of 5-FU Based Maintenance Therapy With or Without Panitumumab in Patients With RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX + Panitumumab Recruiting NCT03300609 Phase 3 Oxaliplatin;Leucovorin Calcium;Fluorouracil;Capecitabine
18 Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy With or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer Recruiting NCT02997228 Phase 3 Atezolizumab;Fluorouracil;Leucovorin Calcium;Oxaliplatin
19 Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superiority Study Recruiting NCT02758951 Phase 2, Phase 3
20 TACE Associated With Systemic Chemotherapy Versus Systemic Chemotherapy in Patients Who Failed With First Line Chemotherapy Active, not recruiting NCT03783559 Phase 3 TACE;chemotherapy±target therapy
21 Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma. A Phase 3 Randomised Controlled Trial Not yet recruiting NCT03708536 Phase 3 S-1;Bevacizumab;Capecitabine
22 A Phase II Trial Evaluating a Modified Regimen of Oxaliplatin and Capecitabine in First-Line Treatment of Metastatic Colorectal Adenocarcinoma Unknown status NCT01552967 Phase 2 Capecitabine
23 Phase II Study Evaluating the Association of Bevacizumab and Chemotherapy of the Type Modified FOLFIRI 3 in Patients With Metastatic Colorectal Adenocarcinoma Unknown status NCT00544011 Phase 2 capecitabine;fluorouracil;irinotecan hydrochloride
24 Phase II Study Of Radiotherapy And Capecitabine As Pre-Operative Treatment In Patients With Colorectal Cancer Unknown status NCT00075556 Phase 2 capecitabine
25 Phase II Trial Assessing the Impact on the Activity of Daily Living of an Oral Chemotherapy by Capecitabine Associated With an Intravenous Chemotherapy by Oxaliplatin as First Line Treatment of Metastatic Colorectal Adenocarcinoma of Patients Aged Over 70 Unknown status NCT00104689 Phase 2 capecitabine;oxaliplatin
26 Pilot Phase II Study of Safety and Immunogenicity of an ALVAC-CEA/B7.1 Vaccine Administered With Chemotherapy, Alone or in Combination With Tetanus Toxoid, as Compared to Chemotherapy Alone, in Patients With Metastatic Colorectal Adenocarcinoma Unknown status NCT00027833 Phase 2 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
27 A Non Randomized Phase II Trial to Assess Efficacy and Safety of Bevacizumab, Capecitabine and Oxaliplatin as First Line Treatment for Elderly Patients With Metastatic Colorectal Adenocarcinoma, Suitable for Polychemotherapy Treatment Unknown status NCT01067053 Phase 2 bevacizumab, capecitabine, oxaliplatin
28 Randomized Phase 2 Study Comparing Pathological Responses on Colorectal Cancer Metastases After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI Unknown status NCT01858649 Phase 2 Bevacizumab;5 FU;Oxaliplatin;Irinotecan
29 A Phase I/ II Clinical Trial of MDV9300 (Pidilizumab) in Diffuse Intrinsic Pontine Glioma Unknown status NCT01952769 Phase 1, Phase 2
30 Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years Old With a Metastatic Colorectal Adenocarcinoma . Completed NCT02788006 Phase 2 Regorafenib 160 mg
31 A Phase IIa Multicenter Evaluation of The Safety And Efficacy of Weekly Administration of S-8184 Paclitaxel Injectable Emulsion In Second Line Treatment of Patients With Stage III or IV Colorectal Adenocarcinoma Completed NCT00034190 Phase 2 S-8184 Paclitaxel Injectable Emulsion
32 Phase 2 Study of Neoadjuvant 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma Completed NCT00168155 Phase 2 perioperative chemotherapy
33 A Single Arm, Multicenter Phase II Study of Everolimus in Patients With Metastatic Colorectal Adenocarcinoma Whose Cancer Has Progressed Despite Prior Therapy With an Anti-EGFR Antibody (if Appropriate), Bevacizumab, Fluoropyrimidine, Oxaliplatin, and Irinotecan-based Regimens Completed NCT00419159 Phase 2 Everolimus (RAD001)
34 Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma Completed NCT01900717 Phase 2 LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified;LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
35 Phase II, Open Label, Single Center, Two Arm Study Study to Assess the Safety, Tolerance and Efficacy of a 2 mg Dose of G17DT Via Intramuscular Injection in Patients With Advanced Metastatic Colorectal Adenocarcinoma. Completed NCT02181465 Phase 2
36 A Randomized Phase II Trial of Two Dose Levels of ZD1839 (Iressa) (NSC 715055, IND 61187) in Patients With Recurrent Colorectal Adenocarcinoma Completed NCT00025350 Phase 2 gefitinib
37 Regorafenib Assessment in Refractory Advanced Colorectal Cancer Completed NCT01929616 Phase 2 regorafenib
38 A Phase II Clinical, Biological and Pharmacological Study of ZD1839 in Patients With Advanced Colorectal Carcinoma Refractory to 5-Fluorouracil (5-FU) and Irinotecan Chemotherapy Completed NCT00030524 Phase 2 gefitinib
39 A Phase II Trial of Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma Completed NCT00165217 Phase 2 Capecitabine;Thalidomide
40 Phase II Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Administered Intravenously to Patients With Colorectal Adenocarcinoma Previously Untreated for Metastatic Disease Completed NCT00890305 Phase 2 CT-011;FOLFOX
41 A Phase II Trial of Lapatinib and Capectiabine for Patients With Refractory Advanced Colorectal Adenocarcinoma (LAP109859) Completed NCT00574171 Phase 2 lapatinib;Capecitabine
42 A Study of ZD1839 (Iressa) in Combination With Oxaliplatin, 5-Fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Malignancies (Phase I) and Advanced Colorectal Cancers (Phase II) Completed NCT00025142 Phase 2 FOLFOX regimen;fluorouracil;gefitinib;leucovorin calcium;oxaliplatin
43 Randomised Controlled Trial of the Effects of Fish Oil Emulsion in Total Parenteral Nutrition Upon Tumour Vascularity in Patients With Hepatic Colorectal Metastases Completed NCT00942292 Phase 2
44 A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum Completed NCT00056030 Phase 2 fluorouracil;leucovorin calcium;oxaliplatin
45 A Phase II Study Of Oral DJ-927 Administered As A Single Dose Every Three Weeks To Patients With Advanced Or Metastatic Adenocarcinoma Of The Colon Or Rectum Completed NCT00080834 Phase 2 DJ-927
46 A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer Completed NCT00531245 Phase 1, Phase 2 TS-1, oxaliplatin
47 A Randomized, Multicenter, Phase II Study Of Bolus/Infusion 5-FU/LV (de Gramont Regimen) Versus Oxaliplatin And Bolus/Infusion 5-FU/LV (de Gramont Regimen) As Third-Line Treatment Of Patients With Metastatic Colorectal Carcinoma Completed NCT00016198 Phase 2 FOLFOX regimen;fluorouracil;leucovorin calcium;oxaliplatin
48 Phase II Study of Oxaliplatin, Capecitabine, Cetuximab, and Bevacizumab in the Treatment of Metastatic Colorectal Cancer Completed NCT00290615 Phase 2 capecitabine;oxaliplatin
49 A Phase II Study Evaluating the Use of Concurrent Cetuximab, Irinotecan, Oxaliplatin and UFT in the First Line Treatment of Patients With Metastatic Colorectal Cancer Completed NCT01225744 Phase 2 Cetuximab;Irinotecan;Oxaliplatin;UFT
50 Expanded Cohort of Patients With Refractory Metastatic Colorectal Cancer (MCRC) Treated With Bevacizumab and Everolimus Completed NCT00597506 Phase 2 Bevacizumab;Everolimus

Search NIH Clinical Center for Colorectal Adenocarcinoma

Genetic Tests for Colorectal Adenocarcinoma

Anatomical Context for Colorectal Adenocarcinoma

MalaCards organs/tissues related to Colorectal Adenocarcinoma:

40
Colon, Liver, Lung, Breast, Thyroid, Lymph Node, T Cells

Publications for Colorectal Adenocarcinoma

Articles related to Colorectal Adenocarcinoma:

(show top 50) (show all 3429)
# Title Authors PMID Year
1
MSH6 gene pathogenic variant identified in familial pancreatic cancer in the absence of colon cancer. 61
31851094 2020
2
Caspase 3-mediated cytotoxicity of mealworm larvae (Tenebrio molitor) oil extract against human hepatocellular carcinoma and colorectal adenocarcinoma. 61
31816367 2020
3
p,p'-Dichlorodiphenyltrichloroethane promotes aerobic glycolysis via reactive oxygen species-mediated extracellular signal-regulated kinase/M2 isoform of pyruvate kinase (PKM2) signaling in colorectal cancer cells. 61
31724279 2020
4
Targeted suppression of metastasis regulatory transcription factor SOX2 in various cancer cell lines using a sequence-specific designer pyrrole-imidazole polyamide. 61
31879179 2020
5
Size and Importance of Socioeconomic Status-Based Disparities in Use of Surgery in Nonadvanced Stage Gastrointestinal Cancers. 61
31605347 2020
6
Thioredoxin domain-containing protein 9 (TXNDC9) contributes to oxaliplatin resistance through regulation of autophagy-apoptosis in colorectal adenocarcinoma. 61
32029274 2020
7
Induction of growth cessation by acacetin via β-catenin pathway and apoptosis by apoptosis inducing factor activation in colorectal carcinoma cells. 61
31734898 2020
8
Intestinal adenosquamous carcinoma with a synchronous skin metastasis: a immunohistochemical and molecular analysis. 61
31823050 2020
9
From byproduct to a functional ingredient: Camu-camu (Myrciaria dubia) seed extract as an antioxidant agent in a yogurt model. 61
31759605 2020
10
Bioavailability and cytotoxicity of Cerium- (IV), Copper- (II), and Zinc oxide nanoparticles to human intestinal and liver cells through food. 61
31733553 2020
11
Study of the protective effect on damaged intestinal epithelial cells of rat multilineage-differentiating stress-enduring (Muse) cells. 61
31642560 2020
12
Chitosan-modified lipid nanodrug delivery system for the targeted and responsive treatment of ulcerative colitis. 61
31887935 2020
13
Mutational Profile Using Next-Generation Sequencing May Aid in the Diagnosis and Treatment of Urachal Adenocarcinoma. 61
31496327 2020
14
Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2. 61
31838290 2020
15
BMP-9 is a novel marker for colorectal tumorigenesis undergoing the normal mucosa-adenoma-adenocarcinoma sequence and is associated with colorectal cancer prognosis. 61
31897139 2020
16
Integrative systematic review meta-analysis and bioinformatics identifies MicroRNA-21 and its target genes as biomarkers for colorectal adenocarcinoma. 61
31756546 2020
17
Cavitary Lung Lesions From Metastatic Colorectal Adenocarcinoma. 61
31856016 2020
18
Colorectal cancer and trace elements alteration. 61
31954212 2020
19
The Impact of Delays to Definitive Surgical Care on Survival in Colorectal Cancer Patients. 61
31367895 2020
20
Improving management of comorbidity in patients with colorectal cancer using comprehensive medical assessment: a pilot study. 61
31959129 2020
21
Smoking and Risk of Colorectal Cancer may differ by Anatomical Subsite and Sex. 61
31971226 2020
22
Demethylation of Di-Methylation of Lysine 4 on Histone 3 Is Inhibited by General Control Nondepressible 5-Induced Acetylation of Lysine-Specific Demethylase 1. 61
31982102 2020
23
miR-770-5p modulates resistance to methotrexate in human colorectal adenocarcinoma cells by downregulating HIPK1. 61
31853309 2020
24
The role of tumor budding in colorectal adenocarcinoma: Possible involvement of the intestinal cancer stem cell marker Lgr5. 61
32031119 2020
25
Microsatellite instability in Costa Rican patients with colorectal adenocarcinoma and its association with overall survival and response to fluoropyrimidine-based chemotherapy. 61
31986316 2020
26
The density of infiltrating T cells and macrophages in the parental tumour correlates with growth rate of tumoroids established from colorectal adenocarcinoma. 61
31997501 2020
27
Upregulation of nuclear factor (erythroid-derived 2)-like 2 protein level in the human colorectal adenocarcinoma cell line DLD-1 by a heterocyclic organobismuth(III) compound: Effect of organobismuth(III) compound on NRF2 signaling. 61
32004978 2020
28
Heat shock protein beta 3 (HSPB3) is an unfavorable molecular biomarker in colorectal adenocarcinoma. 61
31709619 2020
29
Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma. 61
31992245 2020
30
Colorectal adenocarcinoma with enteroblastic differentiation: a clinicopathological study of five cases. 61
31429980 2020
31
Tumor budding is an adverse prognostic marker in intestinal-type sinonasal adenocarcinoma and seems to be unrelated to epithelial-mesenchymal transition. 61
31980958 2020
32
Abundance of Lactobacillus plantarum Strains with Beneficial Attributes in Blackberries (Rubus sp.), Fresh Figs (Ficus carica), and Prickly Pears (Opuntia ficus-indica) Grown and Harvested in Algeria. 61
31981113 2020
33
Trametinib activity in patients with solid tumors and lymphomas harboring BRAF non-V600 mutations or fusions: results from NCI-MATCH (EAY131). 61
31924734 2020
34
Anti-Tumor Activity of Atractylenolide I in Human Colon Adenocarcinoma In Vitro. 61
31947901 2020
35
Effect of Protein Corona on The Transfection Efficiency of Lipid-Coated Graphene Oxide-Based Cell Transfection Reagents. 61
32019150 2020
36
COUP-TFII Knock-down Promotes Proliferation and Invasion in Colorectal Cancer Cells via Activation of Akt Pathway and Up-regulation of FOXC1. 61
31892566 2020
37
Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin-Induced Toxicity in Colorectal Cancer. 61
31936237 2020
38
COL1A1 and MZB1 as the hub genes influenced the proliferation, invasion, migration and apoptosis of rectum adenocarcinoma cells by weighted correlation network analysis. 61
31901757 2020
39
Polyethylene Glycol-Chitosan Oligosaccharide-Coated Superparamagnetic Iron Oxide Nanoparticles: A Novel Drug Delivery System for Curcumin Diglutaric Acid. 61
31906490 2020
40
Mutated CEACAMs Disrupt Transforming Growth Factor Beta Signaling and Alter the Intestinal Microbiome to Promote Colorectal Carcinogenesis. 61
31585122 2020
41
The Prognostic Value of m6A RNA Methylation Regulators in Colon Adenocarcinoma. 61
31823961 2019
42
Dietary Fucoxanthin Induces Anoikis in Colorectal Adenocarcinoma by Suppressing Integrin Signaling in a Murine Colorectal Cancer Model. 61
31905803 2019
43
Glycolysis gene expression profilings screen for prognostic risk signature of hepatocellular carcinoma. 61
31790363 2019
44
RET fusions in solid tumors. 61
31715421 2019
45
Alkynyl Gold(I) complexes derived from 3-hydroxyflavones as multi-targeted drugs against colon cancer. 61
31546196 2019
46
The fatty acid derivative palmitoylcarnitine abrogates colorectal cancer cell survival by depleting glutathione. 61
31483701 2019
47
Breast metastasis from colorectal cancer treated by multimodal therapy: Case report and literature review. 61
31860952 2019
48
Development of Lactobacillus kimchicus DCY51T-mediated gold nanoparticles for delivery of ginsenoside compound K: in vitro photothermal effects and apoptosis detection in cancer cells. 61
30663395 2019
49
Synthesis and cytotoxic activities of novel copper and silver complexes of 1,3-diaryltriazene-substituted sulfonamides. 61
30362387 2019
50
EZH2 Regulates Intestinal Inflammation and Necroptosis Through the JNK Signaling Pathway in Intestinal Epithelial Cells. 61
31273598 2019

Variations for Colorectal Adenocarcinoma

Expression for Colorectal Adenocarcinoma

Search GEO for disease gene expression data for Colorectal Adenocarcinoma.

Pathways for Colorectal Adenocarcinoma

Pathways related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 VEGFA TP53 KRAS HRAS EGFR CTNNB1
2
Show member pathways
13.5 VEGFA KRT7 KRT20 KRAS HRAS EGFR
3
Show member pathways
13.31 VEGFA KRAS HRAS EGFR CTNNB1 CDH1
4
Show member pathways
13.15 TP53 KRAS HRAS EGFR CTNNB1 BRAF
5
Show member pathways
13.07 VEGFA KRAS HRAS EGFR CTNNB1 BRAF
6
Show member pathways
13.02 VEGFA TP53 KRAS HRAS EGFR CTNNB1
7
Show member pathways
12.99 VEGFA TP53 KRAS HRAS EGFR CTNNB1
8
Show member pathways
12.98 VEGFA TP53 KRAS HRAS CTNNB1 CDH1
9
Show member pathways
12.97 VEGFA TP53 KRAS HRAS EGFR CTNNB1
10
Show member pathways
12.93 VEGFA KRAS HRAS EGFR CTNNB1 BRAF
11 12.76 VEGFA TP53 KRAS HRAS EGFR BRAF
12
Show member pathways
12.74 VEGFA TP53 PIM2 MSH2 MLH1 KRAS
13
Show member pathways
12.71 VEGFA KRT20 KRAS HRAS EGFR
14
Show member pathways
12.71 TP53 KRAS HRAS CTNNB1 CDH1 BRAF
15
Show member pathways
12.7 TP53 KRAS HRAS EGFR BRAF
16
Show member pathways
12.7 VEGFA KRAS HRAS EGFR CTNNB1 CDH1
17
Show member pathways
12.69 TP53 MLH1 KRAS HRAS EGFR CTNNB1
18
Show member pathways
12.67 TP53 KRAS HRAS EGFR CDH1 BRAF
19
Show member pathways
12.62 VEGFA TP53 KRAS HRAS EGFR BRAF
20 12.62 VEGFA TP53 PIM2 MSH2 MLH1 KRAS
21
Show member pathways
12.58 TP53 MSH2 KRAS HRAS EGFR CTNNB1
22 12.54 TP53 MSH2 MLH1 CDK8 AURKA
23
Show member pathways
12.53 TP53 KRAS HRAS EGFR BRAF
24 12.52 VEGFA TP53 MIR223 KRAS HRAS EGFR
25
Show member pathways
12.52 TP53 KRAS HRAS EGFR CTNNB1 CDH1
26
Show member pathways
12.46 TP53 KRAS HRAS EGFR CTNNB1
27
Show member pathways
12.41 KRAS HRAS EGFR CTNNB1 CDH1 BRAF
28
Show member pathways
12.4 VEGFA KRAS HRAS CTNNB1 BRAF
29
Show member pathways
12.31 KRAS HRAS FGFBP1 BRAF
30
Show member pathways
12.27 VEGFA KRAS HRAS EGFR
31
Show member pathways
12.26 TP53 KRAS HRAS EGFR BRAF
32 12.26 VEGFA TP53 KRAS HRAS EGFR CTNNB1
33
Show member pathways
12.21 TP53 KRAS HRAS BRAF
34
Show member pathways
12.19 VEGFA TP53 KRAS HRAS BRAF
35
Show member pathways
12.18 TP53 KRAS HRAS BRAF
36 12.17 KRAS HRAS EGFR BRAF AURKA
37
Show member pathways
12.12 KRAS HRAS EGFR BRAF
38 12.1 TP53 MSH2 MLH1 EGFR
39
Show member pathways
12.09 TP53 KRAS HRAS EGFR
40 12.06 KRAS HRAS CTNNB1 CDH1
41 12.03 TP53 KRAS HRAS CTNNB1
42 12.01 TP53 KRAS HRAS CTNNB1
43 11.98 TP53 KRAS HRAS EGFR CTNNB1 BRAF
44
Show member pathways
11.83 KRAS HRAS BRAF
45 11.83 VEGFA TP53 MSH2 MLH1 KRAS EGFR
46 11.77 TP53 MSH2 MLH1
47 11.75 EGFR CTNNB1 CDH1
48 11.73 VEGFA TP53 KRAS HRAS EGFR CDH1
49 11.72 TP53 KRAS HRAS EGFR
50
Show member pathways
11.71 KRAS HRAS BRAF

GO Terms for Colorectal Adenocarcinoma

Cellular components related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.1 MIR223 HRAS EGFR CTNNB1 CDH1 AURKA
2 flotillin complex GO:0016600 8.96 CTNNB1 CDH1

Biological processes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.95 TP53 PIM2 EGFR CTNNB1 CDX2 CDH1
2 in utero embryonic development GO:0001701 9.91 VEGFA TP53 MSH2 CTNNB1
3 regulation of cell proliferation GO:0042127 9.88 TP53 EGFR CTNNB1 BRAF
4 positive regulation of protein phosphorylation GO:0001934 9.85 VEGFA KRAS HRAS EGFR
5 negative regulation of cell proliferation GO:0008285 9.85 TP53 PIM2 HRAS FGFBP1 FABP6 CTNNB1
6 negative regulation of gene expression GO:0010629 9.83 VEGFA TP53 HRAS CTNNB1 AURKA
7 Ras protein signal transduction GO:0007265 9.78 TP53 KRAS HRAS
8 cellular response to drug GO:0035690 9.77 TP53 EGFR BRAF
9 negative regulation of neuron apoptotic process GO:0043524 9.76 MSH2 KRAS HRAS BRAF
10 positive regulation of epithelial cell proliferation GO:0050679 9.74 VEGFA HRAS EGFR
11 positive regulation of cell proliferation GO:0008284 9.7 VEGFA KRAS HRAS FGFBP1 EGFR CTNNB1
12 response to UV-B GO:0010224 9.63 TP53 MSH2
13 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.62 TP53 EGFR
14 positive regulation of isotype switching to IgG isotypes GO:0048304 9.62 MSH2 MLH1
15 positive regulation of fibroblast growth factor receptor signaling pathway GO:0045743 9.6 FGFBP1 CTNNB1
16 entry of bacterium into host cell GO:0035635 9.58 CTNNB1 CDH1
17 response to isolation stress GO:0035900 9.56 KRAS HRAS
18 positive regulation of MAP kinase activity GO:0043406 9.56 VEGFA KRAS HRAS EGFR
19 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.54 VEGFA TP53
20 cellular response to indole-3-methanol GO:0071681 9.52 CTNNB1 CDH1
21 positive regulation of isotype switching to IgA isotypes GO:0048298 9.51 MSH2 MLH1
22 anterior/posterior axis specification GO:0009948 9.5 CTNNB1 CDX2 AURKA
23 positive regulation of gene expression GO:0010628 9.5 VEGFA TP53 MIR223 KRAS HRAS CTNNB1
24 somatic recombination of immunoglobulin gene segments GO:0016447 9.49 MSH2 MLH1
25 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.4 MSH2 MLH1
26 negative regulation of apoptotic process GO:0043066 9.23 VEGFA TP53 PIM2 EGFR CTNNB1 CEACAM5

Molecular functions related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.86 TP53 PIM2 MSH2 MLH1 EGFR CDK8
2 protein kinase binding GO:0019901 9.8 TP53 MSH2 EGFR CTNNB1 AURKA
3 chromatin binding GO:0003682 9.77 TP53 MSH2 MLH1 EGFR CTNNB1
4 protein C-terminus binding GO:0008022 9.62 TP53 MSH2 HRAS CTNNB1
5 enzyme binding GO:0019899 9.55 TP53 MSH2 MLH1 EGFR CTNNB1
6 nucleotide binding GO:0000166 9.1 PIM2 KRAS HRAS EGFR BRAF AURKA
7 guanine/thymine mispair binding GO:0032137 8.96 MSH2 MLH1

Sources for Colorectal Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....